Latest News and Press Releases

AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technologyCollaboration focused on development of dry powder formulations of...

Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1...

Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple...

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate...

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...

Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and...

Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. ...

AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...